TRIM37 promotes tumor cell proliferation and drug resistance in pediatric osteosarcoma
Open Access
- 26 September 2017
- journal article
- Published by Spandidos Publications in Oncology Letters
- Vol. 14 (6), 6365-6372
- https://doi.org/10.3892/ol.2017.7059
Abstract
Osteosarcoma (OS) is among the most frequently occurring bone tumors, particularly in children. Clinical treatment of OS is limited due to several factors including resistance to chemotherapy drugs and metastasis, and the underlying molecular mechanisms remain unclear. In the present study, tripartite motif containing 37 (TRIM37) expression levels were upregulated in tumor samples and associated with the development of drug resistance in OS. Furthermore, chemotherapy drug treatment (doxorubicin, cisplatin and methotrexate) induced TRIM37 expression in OS cells in vitro. TRIM37 mRNA and protein were upregulated in 41 pediatric osteosarcoma clinical specimens. To further elucidate the effect of TRIM37, gain and loss-of-function analysis was performed. Overexpression of TRIM37 induced cell proliferation and drug resistance ability of OS cells, whilst TRIM37 knockdown suppressed cell growth rate and restored chemosensitivity. TRIM37-regulated genes were subsequently analyzed by expression microarray and gene set enrichment analysis. Using the Wnt/β-catenin inhibitor XAV-939, the present study demonstrated that TRIM37-induced chemoresistance is partially dependent on the activation of the Wnt/β-catenin signaling pathway. Collectively, the results of the present study suggest that TRIM37 may have a key role in the development of OS and in the ability for the cells to acquire drug resistance, thus it may be a novel target for the treatment of OS.Keywords
This publication has 25 references indexed in Scilit:
- TRIM37 is a new histone H2A ubiquitin ligase and breast cancer oncoproteinNature, 2014
- Translational biology of osteosarcomaNature Reviews Cancer, 2014
- Osteosarcoma with metastasis at initial diagnosis: Current outcomes and prognostic factors in the context of a comprehensive cancer centerMolecular and Clinical Oncology, 2014
- Osteosarcoma treatment – Where do we stand? A state of the art reviewCancer Treatment Reviews, 2014
- New molecular insights into osteosarcoma targeted therapyCurrent Opinion in Oncology, 2013
- Phase 1 clinical trials for sarcomas: the cutting edgeCurrent Opinion in Oncology, 2011
- Wilms’ tumor and novel TRIM37 mutations in an Australian patient with mulibrey nanismClinical Genetics, 2006
- TRIM37 defective in mulibrey nanism is a novel RING finger ubiquitin E3 ligaseExperimental Cell Research, 2005
- A novel splice site mutation in theTRIM37 gene causes mulibrey nanism in a Turkish family with phenotypic heterogeneityHuman Mutation, 2003
- The TRIM37 Gene Encodes a Peroxisomal RING-B-Box-Coiled-Coil Protein: Classification of Mulibrey Nanism as a New Peroxisomal DisorderAmerican Journal of Human Genetics, 2002